Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD1) or its ligand (PD-L1) have revolutionised the treatment of many malignancies, particularly melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC), however they are not without side effects. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.